Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Intraocular implant for preventing and treating after cataract and preparation method thereof

A technology of implants and preparations, applied in the field of medicine, which can solve the problems of low drug concentration, low drug efficacy, and short duration

Inactive Publication Date: 2009-09-09
SUN YAT SEN UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The present invention studies the shortcomings of the current prevention and treatment of post-disorder drugs, such as low drug efficacy, low drug concentration in the lesion, and short duration of the dosage form, and screens effective drugs for the prevention and treatment of post-disorder, and the design can increase the drug concentration and duration of preparation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Intraocular implant for preventing and treating after cataract and preparation method thereof
  • Intraocular implant for preventing and treating after cataract and preparation method thereof
  • Intraocular implant for preventing and treating after cataract and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] The weight ratio of docetaxel to MMA (methyl methacrylate), HEMA (hydroxyethyl methacrylate) cross-linked copolymer is 1:50

[0038] The ratio of MMA to HEMA is 20:80

[0039] 15 μl of cross-linker EDGMA

[0040] Preparation steps:

[0041] Weigh 100 mg of docetaxel, 1 ml of MMA and 4 ml of HEMA, add 15 μl of cross-linking agent EDGMA and 19 mg of initiator AIBN, sonicate until all solids are completely dissolved, pass through nitrogen protection, pour into a mold, and react at 60°C for 4 day, removed and sterilized. With the phosphate buffer of pH=7.4 as the medium, the in vitro drug release of the preparation was measured, and the results are shown in image 3 .

Embodiment 2

[0043] The specific gravity of docetaxel and auxiliary materials is 1:50, the ratio of slow-release polymer MMA to HEMA is 10:90, 15 μl of cross-linking agent and 19 mg of initiator are added, and the preparation steps are as in Example 1 to prepare docetaxel eye Sustained-release implants. With the phosphate buffer of pH=7.4 as the medium, the in vitro drug release of the preparation was measured, and the results are shown in image 3 .

Embodiment 3

[0045] The specific gravity of docetaxel and auxiliary materials is 1:50, the ratio of sustained-release polymer MMA to HEMA is 30:70, 15 μl of cross-linking agent and 19 mg of initiator are added, the preparation steps are as in Example 1, and the docetaxel eye is prepared. Sustained-release implants. With the phosphate buffer of pH=7.4 as the medium, the in vitro drug release of the preparation was measured, and the results are shown in image 3 .

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to intraocular implant for preventing and treating lens posterior capsule opacification (after cataract), a preparation method thereof and application of Docetaxel in preparing medicines for preventing and treating lens posterior capsule opacification. The implant comprises Docetaxel and at least one kind of polymer carrier, wherein the content of Docetaxel in the preparation is 0.01 to 20 percent; and the mixture ratio of the polymer carrier to medicines ranges from 5:1-10,000:1. The preparation method comprises the following steps: evenly mixing the Docetaxel and polymer carrier monomer in proportion; adding activating substance and / or crosslinking agent and introducing nitrogen for protection; carrying out reaction at a temperature of between 50 and 100 DEG C in a die till the product takes shape; and finally, carrying out sterilization. The medicines and the polymer carrier are made into in-capsule implant and the preparation is implanted into the hollow cavity of a lens capsule after extracapsular cataract extraction to play a role in restraining proliferation of lens epithelial cell for a long time.

Description

Technical field: [0001] The invention belongs to the technical field of medicine, and relates to an intraocular implant for preventing and treating posterior lens capsule turbidity (occlusion) and a preparation method thereof, and the application of docetaxel in preparing a medicine for preventing and treating posterior lens capsule turbidity. Background technique: [0002] Cataract is the first blinding eye disease in humans. There are about 40 million to 45 million blind people in the world, of which 46% are blinded by cataract. Extracapsular cataract extraction is currently the most widely used surgical method in China, while posterior chamber intraocular lens implantation is the most effective method for aphakic refractive correction and has been widely used. However, after extracapsular cataract extraction, posterior capsule opacification (Posterior capsule opacification (PCO)), also known as secondary cataract or post-occurrence disorder, may occur, which is a common c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/337A61K47/32A61K47/34A61K45/06A61P27/02
Inventor 赵春顺易少凌
Owner SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com